KRAS and neoplasm: Moreover, a polygenic risk score that takes into account the interplay of multiple signaling pathways (e.g., the mutated KRAS gene and concomitant high expression of vascular endothelial growth factor) could likely better capture the tumor recurrence phenotype [42].